CurePSP Supports Four New Studies Through its Venture Grants Program

Updated on August 5, 2018

Screen Shot 2018 08 05 at 7.41.42 AM

Research will study genetic factors and tau-protein pathologies in progressive supranuclear palsy (PSP)

CurePSP, the foundation for prime of life neurodegeneration, has funded four grants at a total of more than $300,000 to investigators at universities in the U.S. and Germany for innovative studies in progressive supranuclear palsy (PSP).

PSP is an incurable disease that is part of a spectrum of “prime of life” neurodegenerative afflictions, so named because they most often onset during middle age. These diseases progress rapidly with serious movement, behavioral, emotional, and cognitive symptoms that are largely untreatable.

The studies will investigate genetic factors involved in PSP as well as the behavior of the tau protein, which aggregates into tangles and destroys brain tissue. The tau protein is also involved in Alzheimer’s disease and other neurodegenerative conditions.

The study by Dr. Edward A. Burton of the University of Pittsburgh will identify gene variants that increase or reduce the risk of developing PSP and seek to uncover the biochemical mechanisms involved in the disorder.

Dr. Todd Cohen of the University of North Carolina will investigate tau-protein acetylation as a potential trigger for PSP. Acetylation involves protein modifications within a cell. The goal will be to devise therapies to forestall the abnormal clumping of tau proteins, which could prevent the onset or progression of PSP.

Dr. Thomas Koeglsperger of Ludwig-Maximilians-University of Munich, will study the effect of the gene STX6 on the uptake of tau protein in cultured human neurons. The research will provide further insight into the cause of PSP and support the investigation of new drugs to halt the progression of the disease.
The investigation of Dr. Xiaobo Mao of the Johns Hopkins University School of Medicine will explore a specific mechanism of pathological tau spreading using mouse and cellular models. This may provide a target for drug development.

“We are excited about being able to fund these studies, which were chosen from the largest pool of  Venture Grant applications we have had,” said Dr. Alex Klein, Vice President – Scientific Affairs for the foundation.  “They are approaching research into neurodegeneration from a variety of angles with innovative methods and we expect results that will advance our knowledge of PSP and related diseases.”

CurePSP’s Venture Grants program provides seed capital for early career investigators for targeted research studies. Applications are reviewed by CurePSP’s global Scientific Advisory Board (SAB) and recommended for funding to the foundation’s board of directors.

CurePSP is the foundation for prime of life neurodegeneration, a spectrum of fatal brain disorders that often strike during a person’s most productive and rewarding years. Currently, there is no effective treatment or cure for these diseases, which afflict about 150,000 people in the U.S. According to the National Institutes of Health (NIH), these diseases account for half of all neurodegeneration before the age of 65. Since its founding in 1990, CurePSP has funded more than 190 research studies and is the leading source of support and advocacy for patients, their families, and other caregivers. CurePSP also provides education and awareness to doctors and allied healthcare professionals and the general public. CurePSP is based in New York City. Please visit for more information.

14556571 1295515490473217 259386398988773604 o

The Editorial Team at Healthcare Business Today is made up of skilled healthcare writers and experts, led by our managing editor, Daniel Casciato, who has over 25 years of experience in healthcare writing. Since 1998, we have produced compelling and informative content for numerous publications, establishing ourselves as a trusted resource for health and wellness information. We offer readers access to fresh health, medicine, science, and technology developments and the latest in patient news, emphasizing how these developments affect our lives.